OVIOPEPTIDES

Exclusive Offer

Free Bacteriostatic Water

Sign up and get a free bacteriostatic water added to your next order, automatically.

Research Use OnlyGet free bacteriostatic water added to your next order when you join the list.

BPC-157 — Canada Research Brief

By Dr. Elena Morozova, PhDReviewed by Dr. Elena Morozova, PhDPublished April 11, 2026Last reviewed April 11, 20262 min read
Quick answer

BPC-157 is a 15-amino-acid synthetic peptide derived from a protein in human gastric juice, studied in preclinical research for tissue repair via the VEGFR2 / angiogenesis pathway.

Key facts

Canonical nameBPC-157
Alternate namesBody Protection Compound 157, PL 14736, Bepecin, Pentadecapeptide BPC 157
Drug classSynthetic gastric pentadecapeptide (healing / cytoprotective)
CAS number137525-51-0
Molecular formulaC62H98N16O22
Molecular weight1419.56 g/mol
SequenceGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
COA pending
Research product
US$55.00In stock
View

Origin and structure

BPC-157, short for Body Protection Compound-157, is a synthetic 15-amino-acid peptide derived from a fragment of a larger protein isolated from human gastric juice by Sikiric and colleagues at the University of Zagreb. Unlike most peptides of its size, BPC-157 is reported to be stable in human gastric fluid — a property that drove its initial interest as a potential oral research candidate.

Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Molecular weight: 1,419.56 g/mol. CAS: 137525-51-0.

Preclinical mechanism

Preclinical rodent studies — the vast majority of BPC-157's literature — associate it with three pathways:

  1. VEGFR2 activation and angiogenesis. Several Sikiric-group papers link BPC-157 to upregulation of VEGFR2 expression and new blood-vessel formation in wound sites.
  2. Nitric oxide signalling. BPC-157 appears to interact with NO synthase pathways, which is the most-cited mechanism for its reported cytoprotective effects on the gastric mucosa.
  3. Dopaminergic and serotonergic modulation. A smaller body of work suggests effects on monoamine systems in rodent CNS models.

Human clinical evidence for BPC-157 is essentially absent. There are no completed phase-2 or phase-3 trials in humans registered with ClinicalTrials.gov for orthopaedic, neurological, or gastrointestinal endpoints as of publication.

Canadian research-use framing

BPC-157 is not a Health Canada approved drug, not a prescription item, and not a Natural Health Product. Any Canadian vendor selling BPC-157 as a treatment, therapy, or prescribable substance is operating outside the Food and Drugs Act. OVIOPEPTIDES sells BPC-157 strictly for non-clinical laboratory use. Read our peptides in Canada guide for the full regulatory framing.

Comparisons

Storage and reconstitution

BPC-157 ships as a lyophilised powder. Store the lyophilised vial at -20°C for long-term storage (24+ months) or 4°C for short-term (3-6 months). Reconstitute with bacteriostatic water following the steps in our reconstitution guide. Reconstituted material is stable refrigerated for approximately 2-4 weeks depending on concentration and handling.

Frequently asked questions

What is BPC-157?
BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic pentadecapeptide derived from a protective protein isolated from human gastric juice. It has been studied in rodent preclinical models for roles in tissue repair, gut integrity, and angiogenesis. It is not approved for human use by any regulator.
Is BPC-157 approved in Canada?
No. BPC-157 is not approved by Health Canada for human or veterinary use, not a prescription drug, and not a Natural Health Product. It is sold in Canada strictly as a research chemical for non-clinical laboratory use only.
What is BPC-157's amino acid sequence?
The BPC-157 sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It has a molecular weight of 1,419.56 g/mol, a molecular formula of C62H98N16O22, and CAS number 137525-51-0.
How does BPC-157 differ from TB-500?
BPC-157 is a 15-residue pentadecapeptide derived from gastric juice. TB-500 is a synthetic fragment related to Thymosin Beta-4. Both have been studied in preclinical models for tissue repair, but through different pathways — BPC-157 is associated with VEGFR2/angiogenesis, whereas TB-500 is associated with actin binding and cell migration. Neither is approved for human use.

References

  1. [1]Sikiric P, Seiwerth S, Rucman R, et al.. Stable gastric pentadecapeptide BPC 157 — overview on its effects and mechanisms of action. Current Pharmaceutical Design, 2018. PMID: 29110598
  2. [2]National Center for Biotechnology Information. PubChem CID 9941957 — BPC-157, 2024
  3. [3]Seiwerth S, Rucman R, Turkovic B, et al.. BPC 157 and Blood Vessels. Current Pharmaceutical Design, 2018. PMID: 29769003

Related research